Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting

Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting

The wide use of ruxolitinib, approved for treating primary and secondary myelofibrosis (MF), has revolutionized the landscape of these diseases. This molecule can reduce spleen volume and constitutional symptoms, guaranteeing patients a better quality of life and survival or even a valid bridge to b...

Full description

Bibliographic Details
Main Authors: Andrea Duminuco, Antonella Nardo, Bruno Garibaldi, Calogero Vetro, Anna Longo, Cesarina Giallongo, Francesco Di Raimondo, Giuseppe A. Palumbo
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Clinical Medicine
Subjects:
RR6 prognostic score
myelofibrosis
model validation
ruxolitinib
overall survival
Online Access:https://www.mdpi.com/2077-0383/11/24/7418

Internet

https://www.mdpi.com/2077-0383/11/24/7418

Similar Items